12/22/2025
Another outstanding reason to consider a GLP-1: they can help prevent certain types of breast cancer.
Two studies reported an overall survival benefit of GLP-1 use in certain patients with breast cancer, including those with ductal carcinoma in situ (DCIS) and invasive hormone receptor (HR)-positive nonmetastatic disease, and a third found improvements in a range of toxicities among patients receiving chemotherapy.
These studies, presented during a poster session, add to other emerging research indicating that GLP-1 drugs could have implications across the breast cancer trajectory, including prevention, active therapy, and posttreatment survivorship, explained study discussant Jasmine S. Sukumar, MD, with University of Texas MD Anderson Cancer Center in Houston.
One study focused on the effects of GLP-1 use among patients with HR-positive breast cancer of any stage and obesity who were on adjuvant endocrine therapy.
In a propensity-matched cohort of 8784 GLP-1 users and 8784 nonusers, GLP-1 use was associated with a significant improvement in all-cause mortality after a median follow-up of nearly 6 years (hazard ratio [HR], 0.54; P = .019).
